Compound ID | 3265
Class: Macrolide
| Agent Type: | Semisynthetic; Small molecule; Direct acting; |
| Spectrum of activity: | Gram-negative |
| Mechanism of action: | Protein synthesis inhibitor. Binds to peptidyl transferase centre to prevent translocation |
| Target Pathogen: | Indicated for bovine and swine respiratory tract infections; protein synthesis inhibitor (inactive against macrolide resistant derived ribosomes |
| Description: | Semi-synthetic compound; strains resistant to erythromycin, azithromycin, and tilmicosin are cross-resistant to this compound |
| Institute where first reported: | Pfizer Global Research & Development and Veterinary Medicine Research & Development, Pfizer Inc |
| Year first mentioned: | 2004 |
| Development status: | Experimental |
| External links: | |
| PubChem link: | https://pubchem.ncbi.nlm.nih.gov/compound/9832301 |
| Guide to Pharmacology: | tulathromycin |
| Citation: | https://www.jstage.jst.go.jp/article/antibiotics1968/57/4/57_4_280/_article |